The New Era of Precision Medicine in Oncology | Didactic Presentation and Panel Discussion
contact hours | Knowledge-based
This activity is supported by an
independent educational grant from Merck & Co., Inc.
Advances in cancer
genomics have paved the way for a new era of precision medicine in oncology—an
era in which a patient’s tumor can be characterized extensively for mutations
and other molecular abnormalities, and treatment can be based mainly on the identified
molecular changes (not just the type of cancer). Although these advances are both promising
and exciting, clinicians and payers alike are struggling to translate the results of genetic tumor analysis into
optimal patient care that provides both superior outcomes and satisfactory
session provides an in-depth look at the reality and promise of precision
medicine in oncology. You will learn the
steps involved in going from identifying patients who are candidates for tumor
sequencing to making clinical recommendations based on test results. Along the way, you will become acquainted
with the assays used most commonly to characterize tumors and the evidence
employed to guide patient-specific treatment options. A concluding panel discussion will address
the many challenges posed to payers by a treatment approach still very much in
At the completion of this activity, participants should be
- Define terms used commonly in cancer genomics
and precision medicine.
- Identify the people and tasks associated with
selecting patients for tumor genetic testing and interpreting test
- Explain how an interprofessional molecular tumor
board uses information about a patient’s tumor mutations to inform an
evidence-based treatment plan.
- Recognize possible solutions to challenges
payers face in melding precision medicine with population management.